Back

Unveil the mechanism of Jinzhen Oral Liquid combined with Azithromycin in the treatment of Mycoplasma pneumoniae pneumonia based on Network pharmacology and clinical trials

Zhong, C.; Guo, S.; Liu, Q.; Sun, D.; Wang, B.; Hu, S.; Li, X.; Ding, Y.; Yuan, B.; Liu, J.; Xiang, L.; Li, N.; Xue, Z.; Li, Y.; Teng, Y.; Yi, R.; Li, S.; Ma, R.

2024-06-28 pharmacology and therapeutics
10.1101/2024.06.27.24309347 medRxiv
Show abstract

Mycoplasma pneumoniae pneumonia (MPP) is a common type of pneumonia among school-aged children and adolescents. Jinzhen Oral Liquid (JZOL) and Azithromycin (AZ) are commonly used treatment options in traditional Chinese medicine (TCM) and Western medicine, respectively. There are several clinical and basic research reports on their solo effect against MPP, enabling their combined treatment to become possible. However, the mechanisms and specific pharmacodynamics of their combined therapy remain unclear. In this study, we conducted a mechanistic analysis of the combination of JZOL and AZ based on network target, elucidating their modular network regulatory mechanisms. The modular mechanisms involve four modules, including hormone response, cell differentiation and migration, signal transduction, oxygen and hypoxia response, centered by TNF signaling pathway-mediated regulation. Under the instruction of computational analysis, we conducted a randomized, double-blind, three-armed, parallel-controlled, multicenter clinical study of different doses of JZOL combined with AZ for the treatment of MPP in children. At the study endpoint, the median time to clinical recovery showed statistically significant differences, which were also observed between groups for time to complete fever remission, time to relief of cough/phlegm, effective rate of chest X-ray improvement, and rate of healing of TCM symptoms. During the treatment period, there were no statistically significant differences in the rates of adverse events, serious adverse events, or adverse reactions between the groups. Different doses of JZOL combined with AZ in the treatment of MPP in children have shown the effects of shortening the course of the disease, relieving the symptoms, and improving the prognosis. The research program composed of computational prediction and clinical trials can significantly accelerate the research and development process and identify more effective treatment with good safety, which is worthy of clinical promotion.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
International Immunopharmacology
15 papers in training set
Top 0.1%
13.0%
2
Frontiers in Pharmacology
100 papers in training set
Top 0.2%
10.5%
3
eLife
5422 papers in training set
Top 16%
5.1%
4
Frontiers in Medicine
113 papers in training set
Top 0.9%
4.5%
5
Heliyon
146 papers in training set
Top 0.2%
4.3%
6
PLOS ONE
4510 papers in training set
Top 37%
3.7%
7
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.2%
2.5%
8
Molecular Therapy
71 papers in training set
Top 1%
2.2%
9
Emerging Microbes & Infections
74 papers in training set
Top 0.6%
2.0%
10
Signal Transduction and Targeted Therapy
29 papers in training set
Top 0.5%
2.0%
11
PeerJ
261 papers in training set
Top 6%
1.9%
50% of probability mass above
12
National Science Review
22 papers in training set
Top 0.8%
1.8%
13
Clinical and Translational Science
21 papers in training set
Top 0.4%
1.8%
14
Medicine
30 papers in training set
Top 1.0%
1.8%
15
Aging
69 papers in training set
Top 1%
1.7%
16
The Innovation
12 papers in training set
Top 0.3%
1.7%
17
Journal of Infection
71 papers in training set
Top 1%
1.5%
18
Scientific Reports
3102 papers in training set
Top 61%
1.5%
19
Science Bulletin
22 papers in training set
Top 0.4%
1.4%
20
Genomics, Proteomics & Bioinformatics
171 papers in training set
Top 4%
1.4%
21
Cell Discovery
54 papers in training set
Top 3%
1.4%
22
Acta Pharmaceutica Sinica B
11 papers in training set
Top 0.5%
1.4%
23
International Journal of Molecular Sciences
453 papers in training set
Top 11%
1.0%
24
Acta Biochimica et Biophysica Sinica
19 papers in training set
Top 0.5%
0.9%
25
Annals of Translational Medicine
17 papers in training set
Top 1%
0.8%
26
Briefings in Bioinformatics
326 papers in training set
Top 6%
0.8%
27
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 8%
0.8%
28
Computational and Structural Biotechnology Journal
216 papers in training set
Top 9%
0.8%
29
The FASEB Journal
175 papers in training set
Top 3%
0.8%
30
Atherosclerosis
29 papers in training set
Top 1%
0.8%